Literature DB >> 20122961

Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D2 and D3 dopamine receptors.

Juan Zhen1, Tamara Antonio, Aloke K Dutta, Maarten E A Reith.   

Abstract

In receptor binding assays with ultra-high-affinity radioligands, it is difficult, in practice, to adhere the golden rule that the receptor concentration in the assay should be substantially (at least 10-fold) lower than the dissociation constant (K(d)) of the radioligand and inhibition constant (K(i)) of compound. Especially for low specific activity radioligands (usually tritiated ligands of a couple of TBq/mmol), routinely applied in concentrations at around or below the K(d), the use of extremely small amounts of receptor protein per assay will result in low levels of bound radioactivity; the alternative use of larger assay volumes will make it difficult to apply 96-well filtration devices. For assessing the inhibition constant (K(i)) of competitive inhibitors under conditions violating the above golden rule, equations are available incorporating both [receptor] and [ligand] versus K(d); however, their application requires precise knowledge of [receptor] or initial bound/free [radioligand] ratio. In this study, we present the theoretical basis for determining the K(i) for a competitive inhibitor in a new protocol at high [protein] and high [radioligand] with the simple Cheng-Prusoff correction without the need to correct for [receptor] or initial bound/free [radioligand] ratio. In addition, we present results on the binding of the ultra-high-affinity ligand [(3)H]spiperone to dopamine D(2) and D(3) receptors validating the K(i) values calculated with the new protocol for competitive inhibitors as compared with those calculated with the most comprehensive equation available to date, that of Munson and Rodbard (1988). Binding was measured at varying [radioligand] and [receptor], test compounds (including (-)5-OH-DPAT, (+/-)7-OH-DPAT, and ropinirole) were run with varying [receptor], and simulations were done at vastly varying [radioligand] for inhibitors with vastly different K(i)s. The modified high [radioligand] protocol presented here removes a major hindrance in the proper execution of binding assays with ultra-high-affinity tritiated ligands with K(d) values in the sub-nanomolar range, allowing the use of 96-well plates with small volumes of 100-200 microl per binding assay. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20122961      PMCID: PMC2846987          DOI: 10.1016/j.jneumeth.2010.01.031

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  25 in total

Review 1.  The third dopamine receptor (D3) as a novel target for antipsychotics.

Authors:  P Sokoloff; M P Martres; B Giros; M L Bouthenet; J C Schwartz
Journal:  Biochem Pharmacol       Date:  1992-02-18       Impact factor: 5.858

2.  Quantitative aspects of hormone-receptor interactions of high affinity. Effect of receptor concentration and measurement of dissociation constants of labeled and unlabeled hormones.

Authors:  K J Chang; S Jacobs; P Cuatrecasas
Journal:  Biochim Biophys Acta       Date:  1975-10-06

3.  Estimation of hormone receptor affinity by competitive displacement of labeled ligand: effect of concentration of receptor and of labeled ligand.

Authors:  S Jacobs; P Cuatrecasas
Journal:  Biochem Biophys Res Commun       Date:  1975-09-16       Impact factor: 3.575

4.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

Authors:  P Sokoloff; B Giros; M P Martres; M L Bouthenet; J C Schwartz
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

5.  Potential misconceptions arising from the application of enzyme kinetic equations to ligand-receptor systems at equilibrium.

Authors:  G Tomlinson
Journal:  Can J Physiol Pharmacol       Date:  1988-04       Impact factor: 2.273

6.  An exact correction to the "Cheng-Prusoff" correction.

Authors:  P J Munson; D Rodbard
Journal:  J Recept Res       Date:  1988

7.  Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors.

Authors:  C L Chio; M E Lajiness; R M Huff
Journal:  Mol Pharmacol       Date:  1994-01       Impact factor: 4.436

8.  Site-directed mutagenesis of the human dopamine D2 receptor.

Authors:  A Mansour; F Meng; J H Meador-Woodruff; L P Taylor; O Civelli; H Akil
Journal:  Eur J Pharmacol       Date:  1992-10-01       Impact factor: 4.432

9.  Pharmacological analysis of dopamine stimulation of [35S]-GTP gamma S binding via human D2short and D2long dopamine receptors expressed in recombinant cells.

Authors:  B Gardner; D A Hall; P G Strange
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

10.  D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes.

Authors:  P Werner; N Hussy; G Buell; K A Jones; R A North
Journal:  Mol Pharmacol       Date:  1996-04       Impact factor: 4.436

View more
  9 in total

1.  Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors.

Authors:  Maarten E A Reith; Aloke K Dutta; Dana E Selley; Juan Zhen; Tamara Antonio; Joanna C Jacob; David K Grandy
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

2.  Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.

Authors:  Bhaskar Gopishetty; Suhong Zhang; Prashant S Kharkar; Tamara Antonio; Maarten Reith; Aloke K Dutta
Journal:  Bioorg Med Chem       Date:  2013-04-01       Impact factor: 3.641

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  MHC-I peptide binding activity assessed by exchange after cleavage of peptide covalently linked to β2-microglobulin.

Authors:  Mollie M Jurewicz; Richard A Willis; Vasanthi Ramachandiran; John D Altman; Lawrence J Stern
Journal:  Anal Biochem       Date:  2019-06-13       Impact factor: 3.365

5.  Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies.

Authors:  Sandhya Kortagere; Shu-Yuan Cheng; Tamara Antonio; Juan Zhen; Maarten E A Reith; Aloke K Dutta
Journal:  Biochem Pharmacol       Date:  2010-09-15       Impact factor: 5.858

6.  Deorphanization of novel biogenic amine-gated ion channels identifies a new serotonin receptor for learning.

Authors:  Julia Morud; Iris Hardege; He Liu; Taihong Wu; Myung-Kyu Choi; Swaraj Basu; Yun Zhang; William R Schafer
Journal:  Curr Biol       Date:  2021-08-12       Impact factor: 10.900

7.  Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.

Authors:  Gyan Modi; Chandrashekhar Voshavar; Sanjib Gogoi; Mrudang Shah; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  ACS Chem Neurosci       Date:  2014-07-09       Impact factor: 4.418

8.  Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.

Authors:  Banibrata Das; Seenuvasan Vedachalam; Dan Luo; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2015-11-30       Impact factor: 7.446

9.  Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.

Authors:  Gyan Modi; Tamara Antonio; Maarten Reith; Aloke Dutta
Journal:  J Med Chem       Date:  2014-02-12       Impact factor: 7.446

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.